U.S. Capital Wealth Advisors LLC Trims Position in Bristol Myers Squibb Company (NYSE:BMY)

U.S. Capital Wealth Advisors LLC reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,730 shares of the biopharmaceutical company's stock after selling 11,502 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Bristol Myers Squibb were worth $1,752,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brass Tax Wealth Management Inc. boosted its holdings in shares of Bristol Myers Squibb by 3.4% during the 1st quarter. Brass Tax Wealth Management Inc. now owns 14,554 shares of the biopharmaceutical company's stock valued at $888,000 after acquiring an additional 483 shares during the last quarter. Callan Capital LLC boosted its holdings in shares of Bristol Myers Squibb by 6.8% during the 1st quarter. Callan Capital LLC now owns 6,813 shares of the biopharmaceutical company's stock valued at $416,000 after acquiring an additional 431 shares during the last quarter. Hexagon Capital Partners LLC boosted its holdings in shares of Bristol Myers Squibb by 3.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 17,841 shares of the biopharmaceutical company's stock valued at $1,088,000 after acquiring an additional 567 shares during the last quarter. Argentarii LLC boosted its holdings in shares of Bristol Myers Squibb by 122.0% in the first quarter. Argentarii LLC now owns 9,755 shares of the biopharmaceutical company's stock worth $595,000 after buying an additional 5,361 shares during the last quarter. Finally, Compass Wealth Management LLC boosted its holdings in shares of Bristol Myers Squibb by 68.2% in the first quarter. Compass Wealth Management LLC now owns 3,698 shares of the biopharmaceutical company's stock worth $226,000 after buying an additional 1,500 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Morgan Stanley cut their price objective on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a research report on Thursday. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Finally, William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $57.69.

Bristol Myers Squibb Stock Down 3.3%

NYSE:BMY traded down $1.61 during mid-day trading on Friday, reaching $46.91. The company's stock had a trading volume of 13,380,428 shares, compared to its average volume of 12,865,642. Bristol Myers Squibb Company has a 1 year low of $39.93 and a 1 year high of $63.33. The stock has a fifty day moving average of $47.58 and a 200-day moving average of $53.35. The firm has a market capitalization of $95.47 billion, a PE ratio of 17.57, a price-to-earnings-growth ratio of 1.41 and a beta of 0.36. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company's quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($4.40) earnings per share. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is 92.88%.

Insider Activity at Bristol Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president owned 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.